J&J’s AKEEGA Wins FDA Approval After Cutting Progression Risk by More Than Half in BRCA2-Mutated mCSPC

Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA® (n...

December 15, 2025 | Monday | News
Subsense Expands Funding to $27M Following Early Breakthroughs in Nanoparticle BCI Development

After achieving early breakthroughs in materials development, in vitro nanoparticle stimulation and signal reading, Subsense secures additional $10 mil...

December 12, 2025 | Friday | News
Ginkgo Bioworks Joins Deep Origin To Build ARPA H Funded Computational Drug Safety Platform

Ginkgo Bioworks  announced its partnership with Deep Origin on a 4.5-year project funded by the Advanced Research Projects Agency for Health (ARPA-H...

December 10, 2025 | Wednesday | News
Viatris Secures $815 Million in Strategic Exit From Biocon Biologics Stake

Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Co...

December 08, 2025 | Monday | News
Bayer Initiates Phase IIa ASSESS Trial of Investigational Antibody BAY 3401016 for Alport Syndrome

BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involve...

December 05, 2025 | Friday | News
Taiho Oncology Europe Announces UK Launch of Lytgobi (Futibatinib) for Eligible Patients With Locally Advanced or Metastatic Cholangiocarcinoma

Taiho Oncology Europe GmbH announced the UK launch of Lytgobi® (futibatinib), an irreversibly binding fibroblast growth factor receptor (FGFR) inhibi...

December 04, 2025 | Thursday | News
VNA-318 Demonstrates Strong Target Engagement and Safety in First-in-Human Trial

VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation and improve mitochondrial function First-i...

December 03, 2025 | Wednesday | News
Cullinan’s FLT3-Targeted T Cell Engager CLN-049 Receives FDA Fast Track for R/R AML

Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad populati...

December 02, 2025 | Tuesday | News
Imugene and JW Therapeutics Collaborate on Innovative CF33-CD19 and CAR-T Therapy for Solid Tumors

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlyt...

December 01, 2025 | Monday | News
Arletta Pharma Emerges from Freya Pharma Rebranding to Focus on Women’s Sexual Health

New name reflects company’s transformation as it advances toward the final phase of Lybrido™’s clinical development The Arletta but...

December 01, 2025 | Monday | News
InnoCare Pharma Doses First Patient in Global Phase II Trial of Soficitinib for Prurigo Nodularis

InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced tha...

December 01, 2025 | Monday | News
Eisai and Biogen Submit Subcutaneous Lecanemab (LEQEMBI®) Application to Japan’s PMDA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachuse...

December 01, 2025 | Monday | News
USPTO Grants Notice of Allowance for Enveric’s EVM401 Neuroplastogen Patent

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-m...

November 27, 2025 | Thursday | News
BriaPro Launches AI-Driven Collaboration With Receptor.AI to Design Isoform-Selective Anti-Cancer Kinase Inhibitors

Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary Partners...

November 21, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close